abt-652 + nonsteroidal anti-inflammatory drug

**ABT-652 + nonsteroidal anti-inflammatory drug** is a combination therapy involving **ABT-652**, a small molecule **Histamine H3 receptor modulator**, and a **nonsteroidal anti-inflammatory drug (NSAID)**. ABT-652 was developed by AbbVie (originally Abbott Laboratories) and investigated primarily as a treatment for pain and sleep disorders[1][3]. In clinical settings, this combination was specifically studied for **osteoarthritis of the knee** in patients who experienced only partial benefit from an NSAID alone. The drugs were administered together to assess whether ABT-652 could enhance analgesic efficacy when added to standard NSAID therapy. ABT-652 acts via the **Histamine H3 receptor** as a modulator, potentially affecting neurotransmission involved in neuropathic and musculoskeletal pain as well as sleep regulation[1][3]. NSAIDs act as cyclooxygenase (COX) inhibitors to reduce inflammation and pain. No unique brand or trade name was assigned to the combination; studies referred to it as ABT-652 in combination with an NSAID.